Tumor News and Research

RSS

SDI and CSD announce launch of oncology therapeutic market research service

SDI and Cegedim Strategic Data (CSD) announced today that they will jointly launch a new market research service that tracks selling activities in the oncology therapeutic market. The Oncology Selling Audit will be released in January 2011; 2 years of history will be available for reporting and analysis.

30 Nov 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

IMRISneuro sold to Dartmouth-Hitchcock Medical Center

IMRIS Inc. today announced the sale of IMRISneuro to Dartmouth-Hitchcock Medical Center ("DHMC") in Lebanon, New Hampshire.

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Personalized oncology requires new paradigm for drug development, experts say

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice this week.

25 Nov 2010

New findings provide insight into brain development

St. Jude Children's Research Hospital investigators have identified key components of a signaling pathway that controls the departure of neurons from the brain niche where they form and allows these cells to start migrating to their final destination. Defects in this system affect the architecture of the brain and are associated with epilepsy, mental retardation and perhaps malignant brain tumors.

25 Nov 2010

Research finds ways to tackle drug resistance in melanoma

The past year has brought to light both the promise and the frustration of developing new drugs to treat melanoma, the most deadly form of skin cancer. Early clinical tests of a candidate drug aimed at a crucial cancer-causing gene revealed impressive results in patients whose cancers resisted all currently available treatments.

25 Nov 2010

Dendritic cell vaccine induces immune responses in patients

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published this week in the journal Clinical Cancer Research, was used after surgical resection of metastatic tumors to try to prevent the growth of additional metastases.

25 Nov 2010

New NIVI tissue-imaging technique can accurately detect cancer cells

The long, anxious wait for biopsy results could soon be over, thanks to a tissue-imaging technique developed at the University of Illinois.

25 Nov 2010

Dr. Yves DeClerck honored as first recipient of Richard Call Family Endowed Chair

Yves A. DeClerck, MD, professor of Pediatrics, Biochemistry and Molecular Biology at the Keck School of Medicine of the University of Southern California, has been inducted as the inaugural holder of the Richard Call Family Endowed Chair in Pediatric Research Innovation.

24 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

The effects of pregnancy on oral health

Even though most people are aware that good oral health is essential for the overall health of both mother and child, misunderstandings about the safety of dental care during pregnancy may cause pregnant women to avoid seeing their dentist. The fact is that dentists can create a treatment plan that is safe, effective, and essential for combating the adverse effects of oral disease during pregnancy.

24 Nov 2010

Amorfix introduces high affinity antibodies against cancer primary cells

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that together with its partner Epitomics, high affinity antibodies to prion protein disease specific epitopes (DSEs) have been produced, which bind preferentially to several cancer primary cells and tumor cell lines, but not normal cells.

24 Nov 2010

New IQQA Suite provides total solutions for liver cancer diagnosis, operative treatment management

EDDA Technology Introduces IQQA-Liver Suite To Provide Dedicated Total Solutions For Liver Cancer Diagnosis And Treatment Management

24 Nov 2010

Magnetic fluid hyperthermia destroys cells inside tumors

Magnetic fluid hyperthermia (MFH) is a promising new cancer treatment that essentially "fries" cells inside tumors. The procedure has been used successfully in prostate, liver, and breast tumors.

24 Nov 2010

Disrupting estrogen pathway can halt expansion of breast cancer stem cells: Research

Breast cancer stem cells (CSCs), the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development.

23 Nov 2010

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the "Electrochemotherapy 1st International Users' Meeting"(Bologna, Italy, November 19-20, 2010).

23 Nov 2010

Aggressive surgery for brain tumors increases survival in children

A new Mayo Clinic study found that children with low-grade brain tumors (gliomas) who undergo aggressive surgery to completely remove the tumor have an increased chance of overall survival. If complete removal is not possible, adding radiation therapy to a less complete surgery provides patients with the same outcomes as a complete removal.

23 Nov 2010

New method to target and destroy cancerous cells using hyperthermia

Using hyperthermia, Virginia Tech engineering researchers and a colleague from India unveiled a new method to target and destroy cancerous cells. The research was presented at the 63rd annual meeting of the American Physical Society Nov. 23 in Long Beach, Calif.

23 Nov 2010